Arcus biosciences stock. People and science are a beautiful combination.

Arcus biosciences stock View real-time stock prices and stock quotes for a full financial overview. The management team acknowledged potential risks and uncertainties that may impact the company’s actual results, as detailed in the company’s most recent quarterly report on Form 10-Q filed with the SEC. 20. 19 during the day, reaching a high of $15. 55. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti The value each RCUS share was expected to gain vs. (NYSE:RCUS) and Taiho Pharmaceutical Co. 9% this past week. 66%. Prior to Sagimet BioSciences, Dr. 00 per share. Arcus’s growing employee base and 2021 stock awards drove an increase in employee compensation costs, including approximately $2. On Friday, Arcus Biosciences Inc (RCUS) stock saw a modest uptick, ending the day at $15. Inhibiting CD39 may increase the amount of ATP in the tumor microenvironment, which could lead to enhanced anti-tumor immune response. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences. --(BUSINESS WIRE)-- Arcus Biosciences, Inc. 00% growth. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, Find the latest news headlines from Arcus Biosciences, Inc. The company focuses on an ATP-adenosine pathway, which is a key driver RCUS | Complete Arcus Biosciences Inc. Stock Equities RCUS US03969F1093 Biotechnology & Medical Research Market Closed - Nyse. 39% from the current RCUS share price of $16. The grants include options to purchase 66,900 shares of common stock at an exercise price of $15. 36 billion. All Analysts Top Analysts Total Analysts . Get the latest Arcus Biosciences, Inc RCUS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Please note that any opinions, estimates or forecasts regarding Arcus Biosciences’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Arcus Biosciences, Inc. 54%), a clinical-stage oncology company, is up big this morning. Get the latest Arcus Biosciences Inc (RCUS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ARC-8 is the Arcus Biosciences (RCUS) - Develops innovative cancer immunotherapies by leveraging underexploited biological opportunities. This means the company’s IP could enhance outcomes if used in Arcus Biosciences is followed by the analysts listed above. Co-Founder notifies of intention to sell stock Dec 18. m. View real-time RCUS stock price and news, along with industry-best analysis. Arcus Biosciences (RCUS) Stock Price Performance. The equity investment and collaboration AXL is a receptor tyrosine kinase that is expressed in a variety of tumors and is correlated with poor prognosis. 28M SA News Tue, Feb. Arcus Biosciences, Inc. According to the research reports of 9 Wall Street equities research analysts At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. Day’s Ms. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co Prior to Genentech, Dr. 71% so far this month. General and administrative expenses were $72. N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Find the latest Arcus Biosciences, Inc. 19% institutional shareholders, 59. (RCUS) Stock 5 Comments 1 Like. Arcus’s growing employee base and 2022 stock awards drove an $8. Arcus Biosciences (RCUS) Stock Key Data. 00, for a total transaction of $53,910. stock information by Barron's. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study What happened. 00M in the quarter ending September 30, 2024, with 50. 2 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire 7 days ago - Arcus Biosciences, Inc. The parties will co-develop Gilead-optioned programs globally and will co-commercialize in View today's Arcus Biosciences Inc stock price and latest RCUS news and analysis. 92 to $14. Find the latest Arcus Biosciences, Inc. View PDF View Form 10K Discover historical prices for RCUS stock on Yahoo Finance. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the Arcus Biosciences, Inc. See updates on stock information on the Arcus Biosciences site and contact Investor Relations here. RCUS stock quote prices, financial information, real-time forecasts, and company news from CNN. Gilead Sciences and Arcus Biosciences have expanded their oncology partnership agreement and announced a significant equity investment and board-level changes. 07% compared to its 12-month average P/E ratio of-4. 5M shares. Arcus Biosciences also provided cash runway projections, indicating the anticipated funding for ongoing operations. 81K Followers. 06: MT Arcus Biosciences, Inc. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), What happened. People and science are a beautiful combination. The low in the last 52 weeks of Arcus Biosciences stock was 13. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. Galzus Research. 8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. future price: according to them, RCUS price has a max estimate of 46. 14% away from the 52-week low. 7 million of increased non-cash stock-based compensation. (NYSE:RCUS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ETCompany ParticipantsPia Eaves – Vice President-Investor Arcus Biosciences (NYSE:RCUS) released its Q2 2024 financial results and provided updates on its clinical pipeline. (RCUS) stock price, news, historical charts, analyst ratings and financial information from WSJ. 97. Price Target . 06. Comparatively, Grifols has a beta of 0. Additionally, the employees received restricted stock units to acquire 33,450 shares of Arcus Biosciences, Inc. George Budwell | Dec 9, 2021 Interactive stock price chart for Arcus Biosciences, Inc. This represents a decrease of-11. Key Data. FOSTER CITY, Calif. 00. Try Now>>See Insiders’ Hot Stocks on TipRanks >> Read More on RCUS:Arcus Biosciences Reports Promising Trial ResultsArcus Biosciences price target raised to $46 from $38 at CitiArcus: HIF-2a FOSTER CITY, Calif. Previous Close. 43 and touched a low of $15. reports have an aggregate usefulness score of 4. RCUS. Arcus is at the forefront of designing combination therapies on a relentless pursuit to investigate new medicines for people with cancer. Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. 00M, up 119. Upside +145. 87, suggesting that its stock price is 13% less volatile than the S&P 500. Other Robinhood Financial fees may apply, check rbnhd. Zimberelimab (zim) is a monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity. 84% from a day low at $14. 8 based on 162 reviews. What was the 52-week high for Arcus View Arcus Biosciences, Inc RCUS investment & stock information. Ratings History. 31% from the prior close of $15. (RCUS) stock, including valuation metrics, financial numbers, share information and more. 4 million for the same period in 2020. com. The stock was sold at an average price of $15. 50. the value that each RCUS share actually gained. 14. The low is $20 issued by HC Wainwright & Co. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21. Arcus Biosciences Stock (NYSE: RCUS) stock price, news, charts, stock research, profile. 08. In the same quarter View the latest Arcus Biosciences Inc. stock was originally listed at a price of $17. 00 in Mar 15, 2018. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study Arcus Biosciences Stock Performance. The institutional investor owned 217,041 shares of the company's stock after acquiring an additional 81,193 shares during the quarter. Why Arcus Biosciences Stock Vaulted Higher in November. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. on Find the latest Arcus Biosciences, Inc. 42B with 91. 06 by 5. Employee Stock Purchase Plan (ESPP) Purchase additional shares of RCUS stock with a 15% discount and a 24-month lookback. stock news by MarketWatch. 17% year-over-year. Learn why RCUS stock could be a strong investment. (NYSE:RCUS - Get Free Report) CFO Robert C. Arcus Biosciences has received a consensus rating of Buy. Morgan Healthcare Conference 2025, Jan-14-2025 03:45 PM Jan. Arcus Biosciences' estimated fair value is US$18. (Nasdaq: GILD) and Arcus Biosciences, Inc. EDT Furthermore, the revision of Arcus’s stock price target from $35 to $46 reflects a substantial projected upside, with the current trading price significantly below this target. 00 USD. 33. Gilead Sciences Inc's Arcus Biosciences shares are currently valued at Arcus Biosciences price target raised to $46 from $38 at Citi Arcus: HIF-2a inhibitor, casdatifan data ‘shows promise’ in ccRCC treatment Arcus Biosciences falls -9. 06M shares representing 32. Arcus Biosciences (RCUS) reported Q3 2024 earnings per share (EPS) of-$1, beating estimates of -$1. Over the last year, Arcus Biosciences Inc has hit prices as high as $36. The oral presentation will highlight data from the 100mg daily monotherapy expansion cohort of ARC-20, a Phase 1/1b study evaluating casdatifan in late-line clear cell renal cell carcinoma (ccRCC). $34. MOST RECENT 2023 Annual Report and Form 10K. Additionally, the employees received restricted stock units to acquire When is Arcus Biosciences' next earnings announcement? View the latest RCUS earnings date, analysts forecasts, earnings history, and conference call transcripts. The enterprise value is $350. Open. --(BUSINESS WIRE)-- Gilead Sciences, Inc. 95% (not including any dividends or View Arcus Biosciences, Inc. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study The P/E ratio for Arcus Biosciences (RCUS) is -4. 1. (RCUS) stock discussion in Yahoo Finance's forum. Shares of Arcus Biosciences (RCUS-4. RCUS has a market cap or net worth of $1. 14: Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q3 Revenue $48M Nov. 72. 93. (As of Friday Closing) Stock Price Previous Close 52 wk Range Market Cap Shares The Arcus Biosciences Inc. Arcus Biosciences GAAP EPS of -$0. Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7 th Annual HealthCONx Conference Date: What happened. . Other stock markets. R&D expenses rose to $115 million due to late-stage programs. 3 million for the full year ended December 31, 2021, compared to $42. 47%, for an annualized return of -2. Arcus News: Arcus Announces Overall Survival Data for Domvanalimab Plus Zimberelimab in ARC-10, a Randomized Study in Patients with PDL-1-High Non-Small Cell Lung Cancer Read More A Novel Approach to a Validated Target Arcus Biosciences, Inc. Buy. 17, revenue of $34M beats by $10. Stock analysis for Arcus Biosciences Inc (RCUS:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Use our organizations and/or internet sites who claim to represent RCUS News. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. 20 or 1. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the closing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15. (RCUS) with real-time updates, full price history, technical analysis and more. 15. (RCUS) Stock GILD 7 Comments 1 Like Jane Street Group LLC grew its holdings in Arcus Biosciences, Inc. 5 which represents a slight increase of $0. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study The Arcus Biosciences Inc (RCUS) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $8. 78. Year to date Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. 05M SA News Wed, Nov. Get the latest Arcus Biosciences Inc (RCUS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. P. 13 and as low as $14. Arcus Biosciences (NYSE: RCUS) is owned by 58. 83% on the last day (Friday, 10th Jan 2025) from $14. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study Arcus Biosciences (NYSE:RCUS) is an oncology biotech that has a few combo therapies that could complement certain disease pathways. According to the current price, Arcus Biosciences is 110. Total Valuation. The above increases in research and development costs were mostly offset by increased cost-sharing reimbursements compared to the same quarter in the prior year. 2 million increase in non-cash stock-based compensation. 41, suggesting that its stock price is 59% less volatile than the S&P 500. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its Arcus Biosciences GAAP EPS of -$1. A high-level overview of Arcus Biosciences, Inc. - 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8, comparing favorably to the current standard-of-care - Initiated Phase 1b expansion Arcus Biosciences, Inc. Arcus maintains a cash runway into 2027 with Arcus Biosciences SEC Filings page can be viewed by filing type, date, description and can be downloaded in multiple formats. Arcus Biosciences Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9. 9811, representing a -40. 85% of the company. Detailed statistics for Arcus Biosciences, Inc. Create real-time notifications to follow any changes in the live stock price. Includes open, high, low, close and volume. Arcus Biosciences Inc has a consensus price target of $37 based on the ratings of 15 analysts. 96 suggests Arcus Biosciences is potentially trading close to its fair value ; The US$33. is ranked # 1. is a biopharmaceutical company in the clinical stage of development that dedicates its efforts to devise and market subsequent generation therapies aimed at combating cancer in the United States. 96, and the lowest is $6. Its current market cap is $1. 126 th in group CPRX. , Ltd. (RCUS-3. 04:00:02 2025-01-13 pm EST 5 Get a complete stock price history for Arcus Biosciences, starting from its first trading day. The highest analyst price target is $10. Amount of Analyst Coverage. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its Quemliclustat is a potent and selective small molecule inhibitor of CD73 that has been shown to block the production of adenosine. 9981. Arcus Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. In another report released today, Barclays also maintained a Buy rating on the Arcus Biosciences, Inc. is ranked # 126. The associated price target remains the same with $22. Share your opinion and gain insight from other stock traders and investors. Arcus was one of the few winners in the turbulent biotech space last month. Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences). The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. The price has fallen in 8 of the last 10 days and is down by -10. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted Find the latest Institutional Holdings data for Arcus Biosciences, Inc. Shares of Arcus Biosciences (RCUS 2. Phase 1/1b results for the etrumadenant combination demonstrated a 4. ATP has an important function as an immune-activating danger signal against cancer cells. Jarrett is an accomplished executive in the healthcare and technology industries. Shares of the cancer specialist Arcus Biosciences (RCUS-2. Consensus Rating . What is RCUS's Earnings Per Share (EPS) forecast for 2024-2026? (NYSE: RCUS) Arcus Biosciences's current Earnings Per Share (EPS) is -$3. 02. Common Stock (RCUS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Gilead Sciences Inc is the largest individual Arcus Biosciences shareholder, owning 30. A list of analyst ratings for Arcus Biosciences (RCUS) stock. 61 Arcus Biosciences, Inc. 07, 2021 Arcus Biosciences (RCUS) Investor Presentation - Slideshow People and science are a beautiful combination. 12. She most recently served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc. 93 beats by $0. Arcus Biosciences Inc’s price is currently up 4. (RCUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) 04:02PM Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update (Business The 10 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 34. It develops immunotherapies for the treatment of cancer. 5 million increase in employee compensation costs, which includes a $0. 94%) jumped by as much as 21% in premarket trading Thursday morning. 90%. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth. Arcus Biosciences (NYSE:RCUS) will present first clinical data from the ARC-20 study at the 2024 EORTC-NCI-AACR Symposium. 5, with a low estimate of 20 and a high estimate of 50. (RCUS) CEO Terry Rosen on Q2 2021 Results - Earnings Call Transcript SA Transcripts Sat, Aug. 76 and a low of $15. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that it has commenced an underwritten public offering of its common stock. The underwriters have also exercised in full their overallotment option to purchase Complete Arcus Biosciences Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. View today's Arcus Biosciences Inc stock price and latest RCUS news and analysis. 1 st Biotech Stocks Prepare For Action In 2025. 3. Explore More Read our latest press releases and announcements Arcus Biosciences, Inc. Options Traders Bet Big on These 3 Tech Arcus Biosciences, Inc. Presents at 43rd Annual J. 00 USD and a min estimate of 20. Share your ideas and get valuable insights from the community of like minded traders and investors Arcus Biosciences has a beta of 0. 20 analyst price target for RCUS is 82% more than our estimate of fair value Arcus Biosciences had revenue of $48. The high is $70 issued by BTIG on August 23, 2023. The stock opened at $15. Watch RCUS chart and read a more detailed Arcus The average Arcus Biosciences stock price prediction forecasts a potential upside of 81. 96 per share, which matched the closing price on December 23, 2024. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held These factors combined suggest a strong competitive position for Arcus Biosciences, justifying Flynn’s Buy rating. The average target predicts an increase of 142. GROUP LEADERSHIP Medical-Biomed/Biotech Group. Data will include safety, efficacy, Get Arcus Biosciences Inc (RCUS. Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated View Arcus Biosciences, Inc. Most Recent Annual Report. 3% Arcus Biosciences, Inc. The biotech's stock is heating up in early morning action today on the news Read about Arcus Biosciences Inc (RCUS:XNYS) stock and today's latest news and financial updates. Common Stock (RCUS Institutional Holdings information can be used to gauge the volatility and value on the company’s Non-cash stock-based compensation expense was $9 million for the third quarter 2024, About Arcus Biosciences. The company's average rating score is 3. The Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference Date: Gilead Sciences and Arcus Biosciences announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21. (RCUS) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. Summary Additional Data Analysts Historical Quotes. 00, your return over the last 6 years would have been -16. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected Dec 18. RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) 05:45PM Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients HAYWARD, Calif. (NYSE: RCUS) today announced an amendment to their collaboration agreement and Detailed statistics for Arcus Biosciences, Inc. 96% Arcus Biosciences insiders, and 0. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage You can buy and sell Arcus Biosciences (RCUS) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. stock was issued. Morgan We've gathered analysts' opinions on Arcus Biosciences, Inc. Arcus Biosciences. 75% for this period. 00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings. Parsey held development roles at Sepracor, Regeneron and Merck and was Assistant HAYWARD, Calif. 96% from the current stock price of 14. Common Stock (RCUS) at Nasdaq. , Q3 2024 Earnings Call, Nov 06, 2024 Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established. 36% decrease from the current price of $15. 13. (RCUS) Q3 2024 Earnings Call Transcript - Seeking Alpha 8 days ago - Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update - Business Wire 9 days ago - Arcus Arcus Biosciences is preparing for a readout at the ASCO Annual Meeting, May 15, 2024 3:38 AM ET Arcus Biosciences, Inc. Gilead will invest $320m in Arcus common stock to Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, 2023 2:25 AM ET Arcus Biosciences, Inc. The reduction of adenosine restores immune function. (NYSE:RCUS - Free Report) by 59. 2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Arcus Biosciences, Inc. The company reported $39 million in revenue, up from $29 million YoY, and a net loss of $93 million, compared to $75 million last year. 9% this past week Simply Wall St. 25 based on 2 Stage Free Cash Flow to Equity ; Current share price of US$17. If you had invested in Arcus Biosciences stock at $17. Employee wellness program. If you are building a properly diversified stock portfolio, the chances are some of your picks will In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study FOSTER CITY, Calif. Specifically, the drugmaker's shares are up by an astounding 84% as of 10:16 a. Arcus Biosciences: Showing There Might Be Something To TIGIT After All Dec 15. 10%) jumped by approximately 31% during the month of November, according to data from S&P Global Market Intelligence. Arcus Biosciences Analyst Ratings. Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. 28, 2023 Roche CEO drags Arcus, iTeos lower after comments on cancer trial Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global Get the Latest News and Ratings for RCUS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. 04, revenue of $48M beats by $9. Columns. View daily, weekly or monthly format back to when Arcus Biosciences, Inc. CD39 is a key enzyme in the tumor microenvironment that degrades adenosine triphosphate (ATP). AXL signaling mediates therapeutic resistance to multiple standard-of-care therapies and creates an immunosuppressive tumor microenvironment. 00% retail investors. Arcus Biosciences (NYSE:RCUS) has granted equity awards to four new employees through its 2020 Inducement Plan. During the last trading day the stock fluctuated 4. 35. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9. 04 to a day high of $14. Goeltz II sold 3,594 shares of the company's stock in a transaction on Tuesday, December 31st. & HAYWARD, Calif. Arcus Biosciences Inc Stock Price History. 42 as of Jan 13, 2025. , and prior to this, was Chief Arcus Biosciences, Inc. • 28 days ago Arcus Biosciences to Participate in the 43rd Annual J. 45%), a clinical-stage biopharmaceutical company, are on the move following a progress report for the company's most valuable asset at the moment What happened. stock price fell by -4. 06, 2024 Earnings history by period FQ2 2024 (Jun 2024) Jason Zemansky, an analyst from Bank of America Securities, maintained the Hold rating on Arcus Biosciences (RCUS – Research Report). As of 20-Dec-2024, Arcus Biosciences’s stock price is $15. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. This brings the company's revenue in the last twelve months to $263. (RCUS) Arcus Biosciences Statistics. 00 beats by $0. HAYWARD, Calif. Common Stock (RCUS) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. co/fees for details. Arcus Biosciences Inc (RCUS) Stock Trading Recap. (RCUS) stock. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage Find the latest Arcus Biosciences Inc (RCUS) discussion and analysis from iHub's community of investors. quc hwc lzkh ulcl epx ecy iwmc vmq qljsvn vdukh